

**STRATEGIC DISCUSSIONS AND FUTURE DIRECTIONS
FOR PANCREATIC CANCER BIOMARKERS**

September 14, 2008

Draft Agenda

1:00 - 1:40pm **Joint Session with the Strategic Discussion on Biomarkers for Breast Cancer Meeting**

Oncotype DX: From Research, to Clinical Validation, to Commercialization

Steve Shak, MD, Genomic Health, Inc (confirmed)

BREAK **Pancreatic meeting participants move to separate room**

SESSION ONE **Case Studies in Biomarker Development, Risk Assessment and Screening**

1:45-1:50 **INTRODUCTION:** Ann Killary and Paul Wagner

1:50-1:55 **PURPOSE:** Sudhir Srivastava

1:55-2:10 **Risk Assessment Models in Pancreatic Cancer**
Gloria Petersen, Mayo Clinic (confirmed)

2:10-2:25 **Risk Assessment Models in Lung Cancer**
Xifeng Wu, MDACC (confirmed)

2:25-2:45 **Genomic Strategies for the Development of Biomarkers for Early Detection of Pancreatic Cancer-Current State of the Field**
Anirban Maitra, JHU (confirmed)

2:45-3:05 **Global genomic strategies for biomarker discovery**
Craig Logsdon, MDACC (confirmed)

3:05-3:25 **Biomarkers and Endoscopic Technologies for Early Detection of Pancreatic Cancer**
Michael Goggins, JHU (confirmed)

3:25-3:35 **Current State of the Reference Sets**
Randall Brand, University of Pittsburgh (tentative)
Margaret Mandelson, Fred Hutchinson (tentative)

BREAK

SESSION TWO Strategic Session Round Table

3:45-4:45

QUESTIONS:

Are we making progress with genomic and proteomic approaches towards developing early detection biomarkers and do we need to make course corrections?

Do we have a strategy for risk assessment of the general population?

Should we be identifying high risk and low risk populations ?

In light of the discussion, are we targeting the right reference sets?

For successful approaches in other cancer types, what was your experience in terms of historical perspectives on initial challenges, support issues, funding, logistics, etc.

How did investigators with successful approaches meet these challenges? What sort of timelines were in place? Looking back, what would you change? Thoughts on future directions?

BREAK

SESSION THREE Problems and Novel Strategies for Biomarker Discovery and Validation

5:00-5:15

Presentation from the Lustgarten Foundation –

Status of Antibody Development

Jim DeCaprio, M.D., Dana Farber Cancer Institute (tentative)

5:15-5:35

EDRN investigator talk

Anna Lokshin, University of Pittsburgh (confirmed)

5:35-5:55

EDRN investigator talk

Tony Hollingsworth, University of Nebraska (confirmed)

5:55-6:10

Company talk- ImmunoPCR by Amplified Proteomics, Inc. –will discuss highly sensitive technology for detection in serum with only a single Ab using immunoPCR. (Is this important for candidates without two good antibodies? (confirmed)

6:10-6:25

Company talk - Assay Designs-from Ab production to ELISA production-Is this a solution for antibody production issues? They will discuss Survivin as a model success story. (confirmed)

6:25-6:45

Discussion